Prescription drug · BLA
Yusimry (adalimumab-aqvh) NDC 70114-220
Adalimumab 40 mg/.8mL · Injection, Solution · Subcutaneous · Coherus BioSciences Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70114-220-02 | 70114022002 | 2 SYRINGE, GLASS in 1 CARTON (70114-220-02) / .8 mL in 1 SYRINGE, GLASSMarketed from Jul 1, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Yusimry
- Generic name (nonproprietary)
- adalimumab-aqvh
- Active ingredients
- Adalimumab — 40 mg/.8mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Coherus BioSciences Inc
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761216
- Marketing start
- Listing expires
- Other FDA classes
- Monoclonal (Chemical structure)Tumor Necrosis Factor Receptor Blocking Activity (Mechanism)
- Identifiers
- Product ID 70114-220_92fff88b-7e54-47b3-92ed-e57bbb9b6a84SPL ID 92fff88b-7e54-47b3-92ed-e57bbb9b6a84SPL set ID cd0e7af2-7704-49ce-bde9-f645294b6788RxCUI 2640389, 2640395, 2640397, 2640400UNII FYS6T7F842
- Pharmacologic class
- Tumor Necrosis Factor Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J0135 — Injection, adalimumab, 20 mg
Billing unit: 20 mg. Units on the claim = dose given ÷ 20 mg.
Adalimumab is usually self-administered and dispensed through a pharmacy benefit. Adalimumab biosimilars are listed under their own names.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470114022002followed by a unit qualifier and the quantityPackage 70114-0220-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. Psoriatic Arthritis (PsA) ( 1.3 ): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs andsym…
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 761216
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-816 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-815 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-210 |